Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Adv Drug Deliv Rev. 2021 Dec 20;181:114086. doi: 10.1016/j.addr.2021.114086

Table 2.

Selected PET and related theranostic agents that have received regulatory approvals or are nearing regulatory approvals.

Agent Name Commercial Name Target Approval Date
68Ga-DOTATATE DOTATATE NETSPOT™ Neuroendocrine 08/21/19
68Ga-PSMA-11 TLX591-CDX  ILLUMET™ Prostate cancer, PSMA 12/01/20
18F-DCFPyL F-18-piflufolastat  PYLARIFY® Prostate cancer, PSMA 05/27/21
177Lu-PSMA-617 Lu 177-dotatate  Lutathera® Neuroendocrine 01/26/18